Indegene Ltd Share Price – NSE /  BSE

Healthcare, Small Cap

Indegene announced that the company's wholly owned subsidiaries, Indegene, Inc. (USA) and Trilogy Writing and Consulting GmbH have, on 31 December 2025, signed a Share Purchase Agreement (SPA) to acquire 100% equity shares in Trilogy Writing & Consulting Inc. (formerly known as Trilogy Writing and Consulting ULC (Canada)) (Trilogy Canada) (Target Company), wholly owned subsidiary of Trilogy Writing and Consulting GmbH.

Consequent to the above Trilogy Writing & Consulting Inc. (formerly known as Trilogy Writing and Consulting ULC (Canada) will cease to be the subsidiary of Trilogy Writing and Consulting GmbH and become the wholly owned subsidiary of Indegene, Inc.

Trilogy Canada specialises in medical writing.

Powered by Capital Market - Live News

Net profit of Indegene rose 11.34% to Rs 102.10 crore in the quarter ended September 2025 as against Rs 91.70 crore during the previous quarter ended September 2024. Sales rose 17.09% to Rs 804.20 crore in the quarter ended September 2025 as against Rs 686.80 crore during the previous quarter ended September 2024.

Powered by Capital Market - Live News

Indegene will hold a meeting of the Board of Directors of the Company on 30 October 2025.

Powered by Capital Market - Live News

Indegene announced the expansion of its Consulting Practice, combining its proven strategy and transformation expertise to help life sciences organizations navigate complex, large-scale transformations across the value chain.

Life sciences companies operate in a dynamic business environment, amidst rapid technology-driven disruption. They are seeking consulting partners who not only advise on strategy but also work alongside them to implement solutions and deliver measurable outcomes. Indegene's integrated consulting practice addresses this exact need, offering clients both strategic insight and hands-on transformation implementation support.

In this context, Indegene is strengthening its Consulting Practice to help life sciences organizations address their most pressing challenges with speed, impact, and accountability. This is another key step in the company's journey to meet the evolving needs of the life sciences industry.

Indegene has named Gobin Chandra as Head of the Integrated Consulting Practice to lead its next phase of growth. Gobin currently leads Indegene's Europe region and oversees key client relationships. He brings deep transformation advisory experience from Bain & Company and will shape the consulting charter across strategy and transformation services.

Indegene has steadily expanded its consulting capabilities over the past decade. The acquisition of DT Consulting in 2020 strengthened the company's strategy consulting expertise across customer experience and digital transformation.

In parallel, Indegene has organically built transformation consulting capabilities over the last few years. To scale this further, Indegene has acquired WARN & Co., a UK-based transformation consulting firm, enhancing its ability to drive large-scale business transformations. WARN & Co. brings deep expertise in helping global organizations design and transition to new operating models, systems, and ways of working.

Powered by Capital Market - Live News